Previous close | 7.79 |
Open | 7.70 |
Bid | 7.24 x 400 |
Ask | 7.30 x 700 |
Day's range | 7.18 - 7.96 |
52-week range | 1.28 - 16.24 |
Volume | |
Avg. volume | 1,019,208 |
Market cap | 513.407M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.40 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.25 |
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Inves
Nkarta stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its lymphoma treatment.
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for